Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biopharma Datebook: What’s On The Agenda This Week

This article was originally published in The Pink Sheet Daily

Executive Summary

Events on tap include release of GWU’s obesity drugs outcomes report, developed at FDA’s request, and the sure-to-be contentious Forest shareholders meeting.

You may also be interested in...



Merck Drops Zocor Combo, But Keeps Going With Tredaptive

A brief mention in an SEC filing revealed that Merck has ceased the development of a combination cholesterol pill; the once hot ‘0524 program had languished in late-stages for several years.

Orexigen On Quicker-Than-Expected Pace To Obtain Data Needed To Re-File NDA For Contrave

During its second quarter earnings call, the biotech said it sees recent FDA approvals of two other obesity drugs as a positive for its own prospects, but it is re-engaging with the agency on why it must perform a cardiovascular-outcomes trial prior to approval.

Forest’s Recent Launches Boosting Diversity, But Gaining Traction Slowly

One exception to the slow-growth outlook is the surprise success of Bystolic (nebivolol), the 16th beta blocker to enter the heavily generalized market, but a product the firm has been able to differentiate more by its tolerability than its efficacy.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel